Pos1245 mortality of Covid-19 in Patients With Rheumatic Diseases: Comparison to the General Population in México

Abstract

Background:COVID-19 outcomes in Mexican patients with rheumatic diseases (RDs) in comparison to general population patients are unknown.Objectives:To compare mortality and hospitalization of COVID-19 patients with RDs and those without.Methods:We included for this study all the Mexican patients with RDs and COVID-19 registered from April 17th to October 30th, 2020 in the COVID-19 Global Rheumatology Alliance registry. We compare clinical and demographic characteristics of patients with RDs and COVID-19 to patients with COVID-19 that were selected randomly from the Mexican Epidemiology database (1:3). A logistic regression analysis was performed to adjust for confusion variables.Results:We included 322 patients with COVID-19 and RDs and 969 controls without RDs. Table 1 shows the demographic characteristics and comorbidities of both groups. Bivariate analysis showed that patients with RDs had higher mortality, were older, and were more frequently hospitalized. Comorbidities, such as diabetes, hypertension, cardiovascular and renal diseases were also more frequent in patients with RDs. In the multivariate analysis, having a RD was no longer associated with mortality (Figure 1).Figure 1.Multivariate analysis of mortalityConclusion:Patients with RDs had higher comorbidities, hospitalizations, and mortality than the general population in the bivariate analysis. However, adjusted multivariate analysis showed that the odds for mortality were not increased because of having a RD. These findings suggest that the increased mortality of Mexican patients with RDs may be explained by the higher frequency of comorbidities in this population.Table 1.Comparison of patients with COVID-19 with and without RDsCOVID-19 patients without RDsCOVID-19 patients with RDsp-valueN969323Age (mean (SD))42.6 (17.4)51.2 (13.9)<0.001Sex = Male (%)455 (47.0)55 (17.0)<0.001Deceased = Yes (%)55 (5.7)43 (13.3)<0.001Hospitalization = Hospitalized (%)164 (16.9)152 (47.1)<0.001Intubation = Yes (%)27 (2.8)32 (11.8)<0.001COPD_Asthma = Yes (%)37 (3.8)15 (4.6)0.522Diabetes = Yes (%)114 (11.8)49 (15.2)0.116Obesity = Yes (%)128 (13.3)21 (6.5)0.001Hypertension = Yes (%)152 (15.8)88 (27.2)<0.001Cardiovascular disease = Yes (%)19 (2.0)14 (4.3)0.02CRF = Yes (%)22 (2.3)17 (5.3)0.007Pregnancy = Yes (%)5 (0.5)2 (0.6)0.827Smoker = Yes (%)86 (8.9)10 (3.1)0.001Abbreviations: RDs, rheumatic diseases; COPD, chronic obstructive pulmonary disease; CRF, chronic renal failure.Disclosure of Interests:None declared

Factors Associated With Mortality in Patients With Immune-Mediated Rheumatic Diseases and COVID-19 From Latin America

“…All variables were collected by self-report, clinical and laboratory examination and/or medical records review, performed by the rheumatologist during patient hospitalization due to COVID-19, or at the patient medical appointment (virtual or face-to-face) performed after SARS-CoV-2 infection, depending on availability. Regarding CMR-COVID Registry, 8 a total of 68 Mexican voluntary rheumatologists collected information of their patients with IMIDs and diagnosis of SARS-CoV-2 infection: all the data were sent to the Mexican College of Rheumatology, verified and included in a database from the C19-GRA. ReumaCoV-Brasil is a multicenter, observational, longitudinal registry designed to monitor adult patients with immune-mediated rheumatic diseases with a confirmed diagnosis of COVID-19, according to the Brazilian Ministry of Health criteria 6,9,10 .…”

“…Details of the design of the SAR-COVID Registry, from Argentina, the CMR-COVID Registry, from Mexico, and the ReumaCoV-Brasil Registry, from Brazil have been described previously. [6][7][8] Briefly, SAR-COVID is a national, multicenter, observational, voluntary registry including adult patients with a rheumatic disease and confirmed SARS-CoV-2 infection. 7 A total of 143 independent rheumatologists from all over Argentina have registered to participate.…”